131 related articles for article (PubMed ID: 24487480)
1. Decreased serum fetuin-A levels and active inflammatory bowel disease.
Ma P; Feng YC
Am J Med Sci; 2014 Jul; 348(1):47-51. PubMed ID: 24487480
[TBL] [Abstract][Full Text] [Related]
2. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease].
Ciećko-Michalska I; Fedak D; Mach T
Przegl Lek; 2010; 67(12):1262-5. PubMed ID: 21591350
[TBL] [Abstract][Full Text] [Related]
3. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease.
Karmiris K; Koutroubakis IE; Xidakis C; Polychronaki M; Voudouri T; Kouroumalis EA
Inflamm Bowel Dis; 2006 Feb; 12(2):100-5. PubMed ID: 16432373
[TBL] [Abstract][Full Text] [Related]
4. Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease.
Koutroubakis IE; Xidakis C; Karmiris K; Sfiridaki A; Kandidaki E; Kouroumalis EA
Eur J Clin Invest; 2006 Feb; 36(2):127-32. PubMed ID: 16436095
[TBL] [Abstract][Full Text] [Related]
5. Resistin is an inflammatory marker of inflammatory bowel disease in humans.
Konrad A; Lehrke M; Schachinger V; Seibold F; Stark R; Ochsenkühn T; Parhofer KG; Göke B; Broedl UC
Eur J Gastroenterol Hepatol; 2007 Dec; 19(12):1070-4. PubMed ID: 17998831
[TBL] [Abstract][Full Text] [Related]
6. The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases.
Lakatos G; Hritz I; Varga MZ; Juhász M; Miheller P; Cierny G; Tulassay Z; Herszényi L
Dig Dis; 2012; 30(3):289-95. PubMed ID: 22722554
[TBL] [Abstract][Full Text] [Related]
7. Peripheral cytokine profile in Chilean patients with Crohn's disease and ulcerative colitis.
Beltrán CJ; Candia E; Erranz B; Figueroa C; Gonzalez MJ; Quera R; Hermoso MA
Eur Cytokine Netw; 2009 Mar; 20(1):33-8. PubMed ID: 19318319
[TBL] [Abstract][Full Text] [Related]
8. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype.
Seow CH; Stempak JM; Xu W; Lan H; Griffiths AM; Greenberg GR; Steinhart AH; Dotan N; Silverberg MS
Am J Gastroenterol; 2009 Jun; 104(6):1426-34. PubMed ID: 19491856
[TBL] [Abstract][Full Text] [Related]
9. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
[TBL] [Abstract][Full Text] [Related]
10. B2 microglobulin: is it a reliable marker of activity in inflammatory bowel disease?
Zissis M; Afroudakis A; Galanopoulos G; Palermos L; Boura X; Michopoulos S; Archimandritis A
Am J Gastroenterol; 2001 Jul; 96(7):2177-83. PubMed ID: 11467650
[TBL] [Abstract][Full Text] [Related]
11. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease.
Straub RH; Vogl D; Gross V; Lang B; Schölmerich J; Andus T
Am J Gastroenterol; 1998 Nov; 93(11):2197-202. PubMed ID: 9820396
[TBL] [Abstract][Full Text] [Related]
12. The circulating common gamma chain (CD132) in inflammatory bowel disease.
Nielsen OH; Kirman I; Johnson K; Giedlin M; Ciardelli T
Am J Gastroenterol; 1998 Mar; 93(3):323-8. PubMed ID: 9517632
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) are higher in ulcerative colitis and correlate with disease activity.
Yilmaz Y; Yonal O; Eren F; Atug O; Hamzaoglu HO
J Crohns Colitis; 2011 Oct; 5(5):402-6. PubMed ID: 21939913
[TBL] [Abstract][Full Text] [Related]
14. Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease.
Caradonna L; Amati L; Lella P; Jirillo E; Caccavo D
Am J Gastroenterol; 2000 Jun; 95(6):1495-502. PubMed ID: 10894586
[TBL] [Abstract][Full Text] [Related]
15. Growth differentiation factor-15 serum concentrations reflect disease severity and anemia in patients with inflammatory bowel disease.
Tonkic A; Kumric M; Akrapovic Olic I; Rusic D; Zivkovic PM; Supe Domic D; Sundov Z; Males I; Bozic J
World J Gastroenterol; 2024 Apr; 30(13):1899-1910. PubMed ID: 38659482
[TBL] [Abstract][Full Text] [Related]
16. Elevated thrombopoietin serum levels in patients with inflammatory bowel disease.
Kapsoritakis AN; Potamianos SP; Sfiridaki AI; Koukourakis MI; Koutroubakis IE; Roussomoustakaki MI; Manousos ON; Kouroumalis EA
Am J Gastroenterol; 2000 Dec; 95(12):3478-81. PubMed ID: 11151880
[TBL] [Abstract][Full Text] [Related]
17. Serum tumor necrosis factor activity in inflammatory bowel disease.
Maeda M; Watanabe N; Neda H; Yamauchi N; Okamoto T; Sasaki H; Tsuji Y; Akiyama S; Tsuji N; Niitsu Y
Immunopharmacol Immunotoxicol; 1992; 14(3):451-61. PubMed ID: 1517530
[TBL] [Abstract][Full Text] [Related]
18. Immunoglobulins and IgG subclasses in patients with inflammatory bowel disease.
Gouni-Berthold I; Baumeister B; Berthold HK; Schmidt C
Hepatogastroenterology; 1999; 46(27):1720-3. PubMed ID: 10430330
[TBL] [Abstract][Full Text] [Related]
19. [Assessment of usefulness of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic antibodies in patients with unspecific inflammatory bowel diseases].
Mokrowiecka A; Gasiorowska A; Małecka-Panas E
Pol Merkur Lekarski; 2004; 17 Suppl 1():22-6. PubMed ID: 15603341
[TBL] [Abstract][Full Text] [Related]
20. Circulating soluble interleukin-2 receptor alpha and beta chain in inflammatory bowel disease.
Nielsen OH; Ciardelli T; Wu Z; Langholz E; Kirman I
Am J Gastroenterol; 1995 Aug; 90(8):1301-6. PubMed ID: 7639234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
